Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label
tabling member	label

Search

1135740

registered interest
date	01/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Human Papillomavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they will place a copy of the World Health Organisation Global Advisory Committee on Vaccine Safety 2019 review of HPV vaccine safety in the Library of the House.
tabling member printed	The Countess of Mar
uin	HL16833
answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>A meeting was held by the Global Advisory Committee on Vaccine Safety (GACVS) on 5 to 6 June 2019. However, the Medicines and Healthcare products Regulatory Agency is not aware of any formal review of human papillomavirus vaccine safety published by GACVS in 2019.</p> answering member printed Baroness Blackwood of North Oxford question first answered 15/07/2019 10:24:58 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1861 label Biography information for The Countess of Mar

1135741

registered interest
date	01/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mefloquine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the European Medicines Agency Pharmacovigilance Risk Assessment Committee’s 2014 report on the toxicity of mefloquine (Larium).
tabling member printed	The Countess of Mar
uin	HL16834
answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>At its meeting in February 2014, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recommended that the product information for mefloquine (Lariam) be amended to state that neuropsychiatric adverse reactions may persist for months, or longer, even after discontinuation of the drug. The Medicines and Healthcare products Regulatory Agency (MHRA) accepted the recommendations and implemented the advice of the PRAC, which is reflected in the United Kingdom product information for mefloquine. In addition, the MHRA has since taken further action to ensure that these risks are adequately conveyed to UK prescribers and patients in the form of improved checklists for healthcare professionals and a patient alert card.</p> answering member printed Baroness Blackwood of North Oxford question first answered 10/07/2019 15:26:45 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1861 label Biography information for The Countess of Mar

1135743

registered interest
date	01/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mattresses: Fire Resistant Materials
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the risks to the neurological development of (1) foetuses, and (2) new-born children, of exposure to polyurethane mattresses treated with chlorinated phosphate flame retardants.
tabling member printed	The Countess of Mar
uin	HL16836
answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>The Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment has considered the evidence on the potential effects of chlorinated and non-chlorinated phosphate flame retardants from all exposure sources, in general. The Committee is preparing a statement on phosphate-based flame retardants and the potential for neurodevelopmental toxicity. It is expected that the statement will be published in summer 2019.</p><p>Chlorinated organophosphorous flame retardants are regulated under the European Union REACH (Restriction, Evaluation, Authorisation and Restriction of Chemicals) regime. The United Kingdom has been proactive in supporting the regulation of flame retardants through REACH. The European Chemicals Agency has announced an intention to restrict a number of chlorinated flame retardants. It is expected that the restriction proposal will be submitted in July 2019, followed by a public consultation.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 15/07/2019 10:24:38 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1861 label Biography information for The Countess of Mar

1131897

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Food Standards Agency: Public Appointments
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government when they intend to approve the appointment of a Chief Executive for the Food Standards Agency; and what has been the cause of the delay.
tabling member printed	The Countess of Mar
uin	HL16315
answer	answer is ministerial correction date of answer 26/06/2019 answer text <p>The appointment is subject to the approval process which governs the Civil Service Commission Recruitment Principles. An announcement will be made once that process has concluded.</p> answering member printed Baroness Blackwood of North Oxford question first answered 26/06/2019 12:11:36 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1861 label Biography information for The Countess of Mar

1131898

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	International Life Sciences Institute
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, following the publication of the study on the International Life Sciences Institute "Are industry-funded charities promoting “advocacy-led studies” or “evidence-based science”?, whether they classify the International Life Sciences Institute as an industry lobby group or a scientific health charity.
tabling member printed	The Countess of Mar
uin	HL16316
answer	answer is ministerial correction date of answer 26/06/2019 answer text <p>The Department funds research via the National Institute for Health Research (NIHR). The NIHR does not itself classify any organisation in terms of charitable status or lobby group. The NIHR regards a charity as a specific type of voluntary organisation which must conform to the regulations set out in charity law particularly the Charities Act 2011. Charity is a legal status for an organisation, not a legal form or organisational structure.</p><p>Any organisation which considers that it can carry out high-quality clinical, applied health or social care research is likely to be eligible for Departmental, NIHR-funded research programmes, either directly or with a partner. There are specific guidance documents setting out eligibility criteria for the NIHR’s programmes which include information on partnership working, funding mechanism and contractual obligations including reporting and disclosure of conflicts of interest.</p> answering member printed Baroness Barran question first answered 26/06/2019 13:13:51 answering member 4703 label Biography information for Baroness Barran
tabling member	1861 label Biography information for The Countess of Mar

1128009

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Children
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what processes are in place to safeguard children with chronic fatigue syndrome and other disorders whose parents have enrolled them on Lightning Process courses; and what evaluation has been undertaken of the (1) benefits, and (2) harms, to those children who have participated in such courses.
tabling member printed	The Countess of Mar
uin	HL15894
answer	answer is ministerial correction date of answer 05/06/2019 answer text <p>The Lightning Process (LP) is not offered as a part of the chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) standard treatments on the National Health Service. Subject to the nature of the safeguarding concerns, issues should be directed to the relevant professional regulator, should the practitioner be a member of a registered profession; the local authority (trading standards office or children’s service), if false claims are being made about the effectiveness of the treatment or welfare of a child is a concern; or the police, if a crime is involved.</p><p>The LP involves a course of three half-days of training aiming to teach participants how to use their brain to improve their body's health.</p><p>A randomised controlled trial with 100 adolescents aged 12-18 was undertaken by researchers in Bristol. Participants were randomised into two groups: those who received standard CFS/ME treatment and those who received the standard treatment plus the LP.</p><p>Researchers found those who received the LP had better physical function, were less tired and less anxious after six months. At 12 months, they had further improvement in physical function, and improved depression scores and school attendance. This research trial had several limitations as set out in the peer reviewed journal article. This was a very small trial and so it would need to be repeated in a much larger group to demonstrate more generalisable findings. Participants were not blinded so their self-reported outcomes might have been biased, for example participants may have been more likely to report positive outcomes because they knew they were getting additional therapy in the LP group. Of all those eligible to participate in the trial, fewer than 30% agreed to take part. Participants in the trial did not have any serious adverse events attributable to either LP or usual care. LP therapy was given in addition to the usual CFS/ME care as a no-treatment control group was not deemed ethical, therefore it cannot be suggested as a replacement for current specialised medical care.</p><p>Independent ethical review ensures that participant safety is at the centre of all research. In the United Kingdom, review by an ethics committee is one of a series of safeguards intended to protect the people taking part in the research. The operating procedure for trials in the UK has inbuilt safeguards designed to protect patients from harm in the event an intervention is ineffective or potentially harmful. Participants are free to withdraw from a study at any time.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 05/06/2019 16:40:17 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1861 label Biography information for The Countess of Mar